

Synthetic Biologics, Inc.
Form 8-K
February 26, 2014

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2014

SYNTHETIC BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation)

1-12584
(Commission File No.)

13-3808303
(IRS Employer Identification No.)

155 Gibbs Street, Suite 412, Rockville, MD 20850

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (734) 332-7800

Edgar Filing: Synthetic Biologics, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective February 26, 2014, Steve H. Kanzer resigned from the Board of Directors of Synthetic Biologics, Inc. (the “Company”), and from all other positions with the Company and its subsidiaries. Mr. Kanzer intends to return his focus to his venture capital and investment banking firms on a full-time basis, and is not resigning due to any disagreement with the Company on any matter related to the Company’s operations, policies or practices. On February 26, 2014, the Company issued the press release attached hereto as Exhibits 99.1 regarding the departure described herein.

The information included in this Item 5.02 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits

Exhibit

Number Description

99.1 Press Release dated February 26, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYNTHETIC BIOLOGICS, INC.

Date: February 26, 2014 By: /s/ C. Evan Ballantyne

Name: C. Evan Ballantyne

Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press Release dated February 26, 2014

-4-